Physician profile

Megan Simpson

Family · Tulsa, OK

NPI 1013419662

$248.64

in general payments reported to CMS, 2019-2025

4 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$194.64

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $106.80 2022-2023 Wolverine Coronary Cutting Balloon, Angiojet Ultra 5000a
Surmodics, INC. $99.39 2023-2024 Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Venous Thrombectomy System, Sublime Radial Access 018 Rx Pta Dilatation Catheter
Pacira Pharmaceuticals Incorporated $23.21 2024 Exparel
Kci USA, INC. $19.24 2023 Prevena, Activ.A.C., Prevena Restor Axioform

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Megan Simpson

$248.64

in general payments reported 2019-2025

Years
2022-2024
Top company
Boston Scientific Corporation

https://glasscript.com/doctor/11096014/megan-simpson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.